PE-22-28 vs Gonadorelin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
PE-22-28
PE-22-28 is a synthetic peptide fragment derived from research on the SAMP8 mouse model of accelerated aging. It has shown potential for enhancing memory and reducing cognitive decline.
Full details →Gonadorelin
Gonadorelin is a synthetic form of gonadotropin-releasing hormone (GnRH). It stimulates the pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), supporting natural hormone production.
Full details →Side-by-Side Comparison
| Aspect | PE-22-28 | Gonadorelin |
|---|---|---|
| Mechanism | Derived from the protein that is deficient in SAMP8 mice. May work by inhibiting protein phosphatase 2A methylesterase, thereby affecting memory-related signaling pathways. | Binds to GnRH receptors in the pituitary gland, triggering pulsatile release of LH and FSH. This stimulates testicular or ovarian function and natural sex hormone production. |
| Typical Dosage | Research protocols vary. Intranasal dosing has been studied at various concentrations. Optimal human dosing not established. | Men: 100-200mcg subcutaneously 2-3 times daily. Women (fertility): Per clinical protocol. HRT support: Often combined with other therapies. |
| Administration | Intranasal administration preferred for CNS delivery. Research compound with limited human use data. | Subcutaneous injection. Pulsatile administration mimics natural GnRH release patterns. Often used during or after testosterone therapy. |
| Side Effects | Very limited human data. Primarily studied in animal models for safety and efficacy. | Headache, flushing, injection site reactions. In women may cause ovarian hyperstimulation. Generally well-tolerated. |
| Best For |